Duk L Na

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2441651/publications.pdf

Version: 2024-02-01

351 papers 8,304 citations

39 h-index 74108 75 g-index

441 all docs

441 docs citations

441 times ranked

10828 citing authors

#	Article	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
3	Brief Screening for Mild Cognitive Impairment in Elderly Outpatient Clinic: Validation of the Korean Version of the Montreal Cognitive Assessment. Journal of Geriatric Psychiatry and Neurology, 2008, 21, 104-110.	1.2	396
4	MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden. Brain, 2017, 140, 1107-1116.	3.7	171
5	Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease. Brain, 2019, 142, 1093-1107.	3.7	164
6	Anatomical heterogeneity of Alzheimer disease. Neurology, 2014, 83, 1936-1944.	1.5	161
7	Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, $2015, 1, 95-102$.	1.8	137
8	Association of Cerebral Amyloid- \hat{l}^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
9	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
10	Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer's disease: A CREDOS study. Comprehensive Psychiatry, 2015, 62, 114-122.	1.5	93
11	Synergistic Effects of Ischemia and β-Amyloid Burden on Cognitive Decline in Patients With Subcortical Vascular Mild Cognitive Impairment. JAMA Psychiatry, 2014, 71, 412.	6.0	90
12	A New Classification System for Ischemia Using a Combination of Deep and Periventricular White Matter Hyperintensities. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 636-642.	0.7	85
13	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ¹⁸ F-AV1451 Positron Emission Tomography Imaging. JAMA Neurology, 2018, 75, 999.	4.5	85
14	The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. Dementia and Neurocognitive Disorders, 2019, 18, 77.	0.4	85
15	Structural Brain Changes after Traditional and Robot-Assisted Multi-Domain Cognitive Training in Community-Dwelling Healthy Elderly. PLoS ONE, 2015, 10, e0123251.	1.1	83
16	Clinical effect of white matter network disruption related to amyloid and small vessel disease. Neurology, 2015, 85, 63-70.	1.5	79
17	Factors Associated with Caregiver Burden in Patients with Alzheimer's Disease. Psychiatry Investigation, 2014, 11, 152.	0.7	78
18	Biological Brain Age Prediction Using Cortical Thickness Data: A Large Scale Cohort Study. Frontiers in Aging Neuroscience, 2018, 10, 252.	1.7	78

#	Article	IF	Citations
19	Gray and white matter changes linking cerebral small vessel disease to gait disturbances. Neurology, 2016, 86, 1199-1207.	1.5	75
20	Shape Changes of the Basal Ganglia and Thalamus in Alzheimer's Disease: A Three-Year Longitudinal Study. Journal of Alzheimer's Disease, 2014, 40, 285-295.	1.2	69
21	Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). Journal of Geriatric Psychiatry and Neurology, 2004, 17, 32-35.	1.2	63
22	Machine learning based hierarchical classification of frontotemporal dementia and Alzheimer's disease. Neurolmage: Clinical, 2019, 23, 101811.	1.4	62
23	Distributed Patterns of Functional Connectivity Predict Working Memory Performance in Novel Healthy and Memory-impaired Individuals. Journal of Cognitive Neuroscience, 2020, 32, 241-255.	1.1	62
24	Nervous system involvement by metastatic hepatocellular carcinoma. Journal of Neuro-Oncology, 1998, 36, 85-90.	1.4	61
25	Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimer's and Dementia, 2015, 11, 494.	0.4	61
26	Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 58-67.	1.2	58
27	Prevalence of the apolipoprotein E $\hat{l}\mu 4$ allele in amyloid \hat{l}^2 positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
28	Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimer's Research and Therapy, 2021, 13, 154.	3.0	57
29	Total MRI Small Vessel Disease Burden Correlates with Cognitive Performance, Cortical Atrophy, and Network Measures in a Memory Clinic Population. Journal of Alzheimer's Disease, 2018, 63, 1485-1497.	1.2	55
30	Fully automated pipeline for quantification and localization of white matter hyperintensity in brain magnetic resonance image. International Journal of Imaging Systems and Technology, 2011, 21, 193-200.	2.7	54
31	Effects of education on aging-related cortical thinning among cognitively normal individuals. Neurology, 2015, 85, 806-812.	1.5	54
32	Influence of ROI selection on resting state functional connectivity: an individualized approach for resting state fMRI analysis. Frontiers in Neuroscience, 2015, 9, 280.	1.4	52
33	Relative impact of amyloid- \hat{l}^2 , lacunes, and downstream imaging markers on cognitive trajectories. Brain, 2016, 139, 2516-2527.	3.7	51
34	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	3.3	51
35	Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiology of Aging, 2017, 59, 210-219.	1.5	50
36	Subcortical Hypointensity in Partial Status Epilepticus Associated with Nonketotic Hyperglycemia. Journal of Neuroimaging, 2003, 13, 259-263.	1.0	48

#	Article	IF	Citations
37	Are depressive symptomatology and self-focused attention associated with subjective memory impairment in older adults?. International Psychogeriatrics, 2014, 26, 573-580.	0.6	45
38	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	2.5	45
39	Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology, 2015, 85, 1687-1693.	1.5	44
40	Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. Alzheimer's Research and Therapy, 2020, 12, 73.	3.0	44
41	A Network Flow-based Analysis of Cognitive Reserve in Normal Ageing and Alzheimer's Disease. Scientific Reports, 2015, 5, 10057.	1.6	43
42	Assessment of Functional Characteristics of Amnestic Mild Cognitive Impairment and Alzheimer's Disease Using Various Methods of Resting-State FMRI Analysis. BioMed Research International, 2015, 2015, 1-12.	0.9	41
43	Cortical superficial siderosis. Neurology, 2015, 84, 849-855.	1.5	41
44	Distinctive Resting State Network Disruptions Among Alzheimer's Disease, Subcortical Vascular Dementia, and Mixed Dementia Patients. Journal of Alzheimer's Disease, 2016, 50, 709-718.	1.2	41
45	Mechanism of the Closing-in Phenomenon in a Figure Copying Task in Alzheimer's Disease Patients. Neurocase, 2004, 10, 393-397.	0.2	40
46	Fully-automated approach to hippocampus segmentation using a graph-cuts algorithm combined with atlas-based segmentation and morphological opening. Magnetic Resonance Imaging, 2013, 31, 1190-1196.	1.0	39
47	Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. Neurobiology of Aging, 2016, 47, 149-156.	1.5	39
48	Anti-apoptotic Effects of Human Wharton's Jelly-derived Mesenchymal Stem Cells on Skeletal Muscle Cells Mediated via Secretion of XCL1. Molecular Therapy, 2016, 24, 1550-1560.	3.7	39
49	Sparse SPM: Group Sparse-dictionary learning in SPM framework for resting-state functional connectivity MRI analysis. NeuroImage, 2016, 125, 1032-1045.	2.1	39
50	Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. Scientific Reports, 2017, 7, 9541.	1.6	39
51	Machine Learning-based Individual Assessment of Cortical Atrophy Pattern in Alzheimer's Disease Spectrum: Development of the Classifier and Longitudinal Evaluation. Scientific Reports, 2018, 8, 4161.	1.6	39
52	Using Individualized Brain Network for Analyzing Structural Covariance of the Cerebral Cortex in Alzheimer's Patients. Frontiers in Neuroscience, 2016, 10, 394.	1.4	38
53	A Nomogram for Predicting Amyloid PET Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 681-691.	1.2	38
54	Topographical Heterogeneity of Alzheimer's Disease Based on MR Imaging, Tau PET, and Amyloid PET. Frontiers in Aging Neuroscience, 2019, 11, 211.	1.7	38

#	Article	IF	CITATIONS
55	Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiology of Aging, 2015, 36, 485-491.	1.5	37
56	Prediction of cognitive impairment via deep learning trained with multi-center neuropsychological test data. BMC Medical Informatics and Decision Making, 2019, 19, 231.	1.5	37
57	Degreeâ€based statistic and center persistency for brain connectivity analysis. Human Brain Mapping, 2017, 38, 165-181.	1.9	36
58	Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia. Neurobiology of Aging, 2014, 35, 1213.e13-1213.e17.	1.5	35
59	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.4	35
60	White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers. Journal of Alzheimer's Disease, 2014, 40, 877-886.	1.2	34
61	Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia linked CSF1R mutation: Report of four Korean cases. Journal of the Neurological Sciences, 2015, 349, 232-238.	0.3	33
62	Distribution of human umbilical cord blood-derived mesenchymal stem cells in the Alzheimer's disease transgenic mouse after a single intravenous injection. NeuroReport, 2016, 27, 235-241.	0.6	33
63	Activin A secreted by human mesenchymal stem cells induces neuronal development and neurite outgrowth in an in vitro model of Alzheimer's disease: neurogenesis induced by MSCs via activin A. Archives of Pharmacal Research, 2016, 39, 1171-1179.	2.7	33
64	Retinal microvasculature changes in amyloid-negative subcortical vascular cognitive impairment compared to amyloid-positive Alzheimer's disease. Journal of the Neurological Sciences, 2019, 396, 94-101.	0.3	33
65	Influence of personality on depression, burden, and health-related quality of life in family caregivers of persons with dementia. International Psychogeriatrics, 2017, 29, 227-237.	0.6	32
66	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study. Scientific Reports, 2017, 7, 1910.	1.6	32
67	[18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia. Alzheimer Disease and Associated Disorders, 2018, 32, 62-69.	0.6	32
68	Cognitive Profiles and Neuropsychiatric Symptoms in Korean Early-Onset Alzheimer's Disease Patients: A CREDOS Study. Journal of Alzheimer's Disease, 2015, 44, 661-673.	1.2	31
69	Unstable Body Mass Index and Progression to Probable Alzheimer's Disease Dementia inÂPatients with Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 483-491.	1.2	31
70	Glucose Metabolic Brain Networks in Early-Onset vs. Late-Onset Alzheimer's Disease. Frontiers in Aging Neuroscience, 2016, 8, 159.	1.7	31
71	Clinical significance of amyloid \hat{l}^2 positivity in patients with probable cerebral amyloid angiopathy markers. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1287-1298.	3.3	31
72	Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment. Neurobiology of Aging, 2014, 35, 291-300.	1.5	30

#	Article	IF	CITATIONS
73	Prediction Model of Conversion to Dementia Risk in Subjects with Amnestic Mild Cognitive Impairment: A Longitudinal, Multi-Center Clinic-Based Study. Journal of Alzheimer's Disease, 2017, 60, 1579-1587.	1.2	30
74	White Matter Network Disruption and Cognitive Dysfunction in Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2018, 9, 1104.	1.1	30
75	Amyloid involvement in subcortical regions predicts cognitive decline. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2368-2376.	3.3	30
76	Effects of Amyloid and Small Vessel Disease on White Matter Network Disruption. Journal of Alzheimer's Disease, 2015, 44, 963-975.	1.2	29
77	Combined effects of physical exercise and education on age-related cortical thinning in cognitively normal individuals. Scientific Reports, 2016, 6, 24284.	1.6	28
78	Synergistic effects of longitudinal amyloid and vascular changes on lobar microbleeds. Neurology, 2016, 87, 1575-1582.	1.5	28
79	Preoperative biomarkers in patients with idiopathic normal pressure hydrocephalus showing a favorable shunt surgery outcome. Journal of the Neurological Sciences, 2018, 387, 21-26.	0.3	28
80	Prognostic value of amyloid PET scan in normal pressure hydrocephalus. Journal of Neurology, 2018, 265, 63-73.	1.8	28
81	Frontal-executive dysfunction affects dementia conversion in patients with amnestic mild cognitive impairment. Scientific Reports, 2020, 10, 772.	1.6	27
82	Clinical practice guideline for dementia by Clinical Research Center for Dementia of South Korea. Journal of the Korean Medical Association, 2011, 54, 861.	0.1	26
83	Intra-Arterially Delivered Mesenchymal Stem Cells Are Not Detected in the Brain Parenchyma in an Alzheimer's Disease Mouse Model. PLoS ONE, 2016, 11, e0155912.	1.1	26
84	Longitudinal outcomes of amyloid positive versus negative amnestic mild cognitive impairments: a three-year longitudinal study. Scientific Reports, 2018, 8, 5557.	1.6	26
85	Differential effects of white matter hyperintensity on geriatric depressive symptoms according to APOE-ε4 status. Journal of Affective Disorders, 2015, 188, 28-34.	2.0	25
86	iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. Experimental Neurobiology, 2018, 27, 350-364.	0.7	25
87	Analysis of frontotemporal dementia, amyotrophic lateral sclerosis, and other dementia-related genes in 107 Korean patients with frontotemporal dementia. Neurobiology of Aging, 2018, 72, 186.e1-186.e7.	1.5	25
88	Non-monotonic reorganization of brain networks with Alzheimer's disease progression. Frontiers in Aging Neuroscience, 2015, 7, 111.	1.7	24
89	Occupational Attainment as Risk Factor forÂProgression from Mild Cognitive Impairment to Alzheimer's Disease: AÂCREDOS Study. Journal of Alzheimer's Disease, 2016, 55, 283-292.	1.2	24
90	PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 1563-1576.	1.2	24

#	Article	IF	CITATIONS
91	Magnetic Resonance Imaging of Ferumoxytol-Labeled Human Mesenchymal Stem Cells in the Mouse Brain. Stem Cell Reviews and Reports, 2017, 13, 127-138.	5. 6	24
92	Exposure to ambient fine particles and neuropsychiatric symptoms in cognitive disorder: A repeated measure analysis from the CREDOS (Clinical Research Center for Dementia of South Korea) study. Science of the Total Environment, 2019, 668, 411-418.	3.9	24
93	Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. Scientific Reports, 2020, 10, 14950.	1.6	24
94	Validation of the Korean version of the Bayer activities of daily living scale. Human Psychopharmacology, 2003, 18, 469-475.	0.7	23
95	Corpus Callosum Atrophy in Wernicke's Encephalopathy. Journal of Neuroimaging, 2005, 15, 367-372.	1.0	23
96	Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI). Archives of Gerontology and Geriatrics, 2009, 49, 204-207.	1.4	23
97	Pyramidal and extrapyramidal scale (PEPS): A new scale for the assessment of motor impairment in vascular cognitive impairment associated with small vessel disease. Clinical Neurology and Neurosurgery, 2011, 113, 181-187.	0.6	23
98	Classifying anatomical subtypes of subjective memory impairment. Neurobiology of Aging, 2016, 48, 53-60.	1.5	23
99	A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1938-1948.	3.3	23
100	A Comparison of Immune Responses Exerted Following Syngeneic, Allogeneic, and Xenogeneic Transplantation of Mesenchymal Stem Cells into the Mouse Brain. International Journal of Molecular Sciences, 2020, 21, 3052.	1.8	23
101	Intrathecal Injection in a Rat Model: A Potential Route to Deliver Human Wharton's Jelly-Derived Mesenchymal Stem Cells into the Brain. International Journal of Molecular Sciences, 2020, 21, 1272.	1.8	22
102	Albuminuria, Cerebrovascular Disease and Cortical Atrophy: among Cognitively Normal Elderly Individuals. Scientific Reports, 2016, 6, 20692.	1.6	21
103	Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. Alzheimer Disease and Associated Disorders, 2017, 31, 13-18.	0.6	21
104	Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model. Scientific Reports, 2017, 7, 39340.	1.6	21
105	Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Neurolmage: Clinical, 2019, 24, 101941.	1.4	21
106	Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. Scientific Reports, 2019, 9, 1814.	1.6	21
107	NOTCH3 variants in patients with subcortical vascular cognitive impairment: a comparison with typical CADASIL patients. Neurobiology of Aging, 2015, 36, 2443.e1-2443.e7.	1.5	20
108	Distribution of human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs) in canines after intracerebroventricular injection. Neurobiology of Aging, 2016, 47, 192-200.	1.5	20

#	Article	IF	CITATIONS
109	Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Scientific Reports, 2021, 11, 6954.	1.6	20
110	T1-weighted Axial Visual Rating Scale for an Assessment of Medial Temporal Atrophy in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 169-178.	1.2	19
111	Association between body mass index and cortical thickness: among elderly cognitively normal men and women. International Psychogeriatrics, 2015, 27, 121-130.	0.6	19
112	Strictly Lobar Microbleeds Reflect Amyloid Angiopathy Regardless of Cerebral and Cerebellar Compartments. Stroke, 2020, 51, 3600-3607.	1.0	19
113	Amyloid Positivity in the Alzheimer/Subcortical-Vascular Spectrum. Neurology, 2021, 96, e2201-e2211.	1.5	19
114	Body Mass Index and Mortality Rate in Korean Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 399-406.	1.2	18
115	Early- vs late-onset subcortical vascular cognitive impairment. Neurology, 2016, 86, 527-534.	1.5	18
116	18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2017, 57, 711-716.	1.2	18
117	Clinical characteristics of parkinsonism in frontotemporal dementia according to subtypes. Journal of the Neurological Sciences, 2017, 372, 51-56.	0.3	18
118	Menopausal hormone therapy and mild cognitive impairment: a randomized, placebo-controlled trial. Menopause, 2018, 25, 870-876.	0.8	18
119	Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. Scientific Reports, 2020, 10, 19576.	1.6	18
120	Clinical and Neuropsychological Characteristics of a Nationwide Hospital-Based Registry of Frontotemporal Dementia Patients in Korea: A CREDOS-FTD Study. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 242-251.	0.6	17
121	Trajectories of Physiological Brain Aging and Related Factors in People Aged from 20 to over-80. Journal of Alzheimer's Disease, 2018, 65, 1237-1246.	1.2	17
122	The Effects of Longitudinal White Matter Hyperintensity Change on Cognitive Decline and Cortical Thinning over Three Years. Journal of Clinical Medicine, 2020, 9, 2663.	1.0	17
123	Higher education affects accelerated cortical thinning in Alzheimer's disease: a 5-year preliminary longitudinal study. International Psychogeriatrics, 2015, 27, 111-120.	0.6	16
124	Decreased hemoglobin levels, cerebral small-vessel disease, and cortical atrophy: among cognitively normal elderly women and men. International Psychogeriatrics, 2016, 28, 147-156.	0.6	16
125	Mortality Risk after Diagnosis of Early-Onset Alzheimer's Disease versus Late-Onset Alzheimer's Disease: A Propensity Score Matching Analysis. Journal of Alzheimer's Disease, 2017, 56, 1341-1348.	1,2	16
126	Amyloid and cerebrovascular burden divergently influence brain functional network changes over time. Neurology, 2019, 93, e1514-e1525.	1.5	16

#	Article	IF	CITATIONS
127	Sex-specific relationship of cardiometabolic syndrome with lower cortical thickness. Neurology, 2019, 93, e1045-e1057.	1.5	16
128	Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 113.	3.0	16
129	Predominant subcortical accumulation of 18 F-flortaucipir binding in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2018, 66, 112-121.	1.5	15
130	The impact of education on cortical thickness in amyloid-negative subcortical vascular dementia: cognitive reserve hypothesis. Alzheimer's Research and Therapy, 2018, 10, 103.	3.0	15
131	Prediction Models of Cognitive Trajectories in Patients with Nonamnestic Mild Cognitive Impairment. Scientific Reports, 2018, 8, 10468.	1.6	15
132	Distinct Brain Regions in Physiological and Pathological Brain Aging. Frontiers in Aging Neuroscience, 2019, 11, 147.	1.7	15
133	Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. Scientific Reports, 2019, 9, 564.	1.6	15
134	Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 292-303.	3.3	15
135	[¹⁸ F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. Journal of Clinical		

#	Article	IF	Citations
145	A Validation Study of the Inbrain CST: a Tablet Computer-based Cognitive Screening Test for Elderly People with Cognitive Impairment. Journal of Korean Medical Science, 2020, 35, e292.	1.1	13
146	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Journal of Korean Medical Science, 2020, 35, e361.	1.1	13
147	Blood Viscosity in Subcortical Vascular Mild Cognitive Impairment with versus without Cerebral Amyloid Burden. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 958-966.	0.7	12
148	The Heterogeneity and Natural History of Mild Cognitive Impairment of Visual Memory Predominant Type. Journal of Alzheimer's Disease, 2014, 43, 143-152.	1.2	12
149	The Role of Cerebrovascular Disease inÂAmyloid Deposition. Journal of Alzheimer's Disease, 2016, 54, 1015-1026.	1.2	12
150	Distinctive Clinical Effects of Haemorrhagic Markers in Cerebral Amyloid Angiopathy. Scientific Reports, 2017, 7, 15984.	1.6	12
151	Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea. Yonsei Medical Journal, 2017, 58, 1055.	0.9	12
152	The Impact of APOE É>4 in Alzheimer's Disease Differs According to Age. Journal of Alzheimer's Disease, 2018, 61, 1377-1385.	1.2	12
153	18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia. Neurobiology of Aging, 2019, 75, 187-197.	1.5	12
154	Clinical significance of focal $\tilde{A}\ddot{Y}$ -amyloid deposition measured by 18F-flutemetamol PET. Alzheimer's Research and Therapy, 2020, 12, 6.	3.0	12
155	Disease progression modeling of Alzheimer's disease according to education level. Scientific Reports, 2020, 10, 16808.	1.6	12
156	Killing two birds with one stone: The multifunctional roles of mesenchymal stem cells in the treatment of neurodegenerative and muscle diseases. Histology and Histopathology, 2018, 33, 629-638.	0.5	12
157	A Comprehensive Evaluation of the Process of Copying a Complex Figure in Early- and Late-Onset Alzheimer Disease: A Quantitative Analysis of Digital Pen Data. Journal of Medical Internet Research, 2020, 22, e18136.	2.1	12
158	Performance of the plasma \hat{A}^242/\hat{A}^240 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. Alzheimer's Research and Therapy, 2021, 13, 179.	3.0	12
159	Apolipoprotein E4 Affects Topographical Changes in Hippocampal and Cortical Atrophy in Alzheimer's Disease Dementia: A Five-Year Longitudinal Study. Journal of Alzheimer's Disease, 2015, 44, 1075-1085.	1.2	11
160	Tract-Specific Correlates of Neuropsychological Deficits in Patients with Subcortical Vascular Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 50, 1125-1135.	1.2	11
161	Predictors of Institutionalization in Patients with Alzheimer's Disease in South Korea. Journal of		

#	Article	IF	CITATIONS
163	Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments. Alzheimer's Research and Therapy, 2019, 11, 10.	3.0	11
164	Risk Factors of Behavioral and Psychological Symptoms in Patients with Alzheimer Disease: The Clinical Research of Dementia of South Korea Study. Korean Journal of Family Medicine, 2019, 40, 16-21.	0.4	11
165	Ethionamide Preconditioning Enhances the Proliferation and Migration of Human Wharton's Jelly-Derived Mesenchymal Stem Cells. International Journal of Molecular Sciences, 2020, 21, 7013.	1.8	11
166	Machine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 143-157.	1.2	11
167	Effect of Background Motion on Line Bisection Performance in Normal Subjects. Cortex, 2002, 38, 787-796.	1.1	10
168	Regional amyloid burden and lacune in pure subcortical vascular cognitive impairment. Neurobiology of Aging, 2017, 55, 20-26.	1.5	10
169	The Impact of Amyloid- \hat{l}^2 or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Journal of Alzheimer's Disease, 2020, 78, 573-585.	1.2	10
170	Helicobacter Pylori Infection Is Associated with Neurodegeneration in Cognitively Normal Men. Journal of Alzheimer's Disease, 2021, 82, 1591-1599.	1.2	10
171	Identification of Heterogeneous Subtypes of Mild Cognitive Impairment Using Cluster Analyses Based on PET Imaging of Tau and Astrogliosis. Frontiers in Aging Neuroscience, 2020, 12, 615467.	1.7	10
172	The Closing-in Phenomenon in Alzheimer's Disease and Vascular Dementia. Journal of Clinical		

#	Article	IF	CITATIONS
181	Coronary artery calcium is associated with cortical thinning in cognitively normal individuals. Scientific Reports, 2016, 6, 34722.	1.6	8
182	Comparison of neuropsychological profiles in patients with Alzheimer's disease and mixed dementia. Journal of the Neurological Sciences, 2016, 369, 134-138.	0.3	8
183	Behavioural and neuropsychiatric disturbance in three clinical subtypes of frontotemporal dementia: A Clinical Research Center for Dementia of South Koreaâ€FTD Study. Australasian Journal on Ageing, 2017, 36, 46-51.	0.4	8
184	Centiloid method evaluation for amyloid PET of subcortical vascular dementia. Scientific Reports, 2017, 7, 16322.	1.6	8
185	Sex-Related Reserve Hypothesis in Alzheimer's Disease: Changes in Cortical Thickness with a Five-Year Longitudinal Follow-Up. Journal of Alzheimer's Disease, 2018, 65, 641-649.	1.2	8
186	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. BMC Neurology, 2019, 19, 211.	0.8	8
187	Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study. Neurobiology of Aging, 2020, 86, 75-80.	1.5	8
188	Reduced forced vital capacity is associated with cerebral small vessel disease burden in cognitively normal individuals. NeuroImage: Clinical, 2020, 25, 102140.	1.4	8
189	PSEN1 variants in Korean patients with clinically suspicious early-onset familial Alzheimer's disease. Scientific Reports, 2020, 10, 3480.	1.6	8
190	Prediction of tau accumulation in prodromal Alzheimer's disease using an ensemble machine learning approach. Scientific Reports, 2021, 11, 5706.	1.6	8
191	Preliminary Study for a Multicenter Study of Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Dementia and Neurocognitive Disorders, 2013, 12, 1.	0.4	8
192	Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. Stroke, 2022, 53, 698-709.	1.0	8
193	Serial Positron Emission Tomography Findings in a Patient with Hydrocephalic Dementia and Alzheimer's Disease. Journal of Neuroimaging, 2004, 14, 170-175.	1.0	7
194	The Effects of Age, Gender, and Hand on Force Control Capabilities of Healthy Adults. Human Factors, 2015, 57, 1348-1358.	2.1	7
195	MRI-defined versus clinically-defined vascular depression; comparison of prediction of functional disability in the elderly. Archives of Gerontology and Geriatrics, 2016, 66, 7-12.	1.4	7
196	A Dextral Primary Progressive Aphasia Patient with Right Dominant Hypometabolism and Tau Accumulation and Left Dominant Amyloid Accumulation. Case Reports in Neurology, 2016, 8, 78-86.	0.3	7
197	Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus		

#	Article	IF	CITATIONS
199	Distribution and clinical impact of apolipoprotein E4 in subjective memory impairment andÂearly mild cognitive impairment. Scientific Reports, 2020, 10, 13365.	1.6	7
200	Development of an Ultrasonic Doppler Sensor-Based Swallowing Monitoring and Assessment System. Sensors, 2020, 20, 4529.	2.1	7
201	The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. Scientific Reports, 2020, 10, 13583.	1.6	7
202	Analyzing the advantages of subcutaneous over transcutaneous electrical stimulation for activating brainwaves. Scientific Reports, 2020, 10, 7360.	1.6	7
203	Effects of Alzheimer's and Vascular Pathologies on Structural Connectivity in Early- and Late-Onset Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 606600.	1.4	7
204	Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population. Alzheimer's Research and Therapy, 2021, 13, 117.	3.0	7
205	Increased telomere length in patients with frontotemporal dementia syndrome. Journal of the Neurological Sciences, 2021, 428, 117565.	0.3	7
206	Improvement of hemispatial neglect by a see-through head-mounted display: a preliminary study. Journal of NeuroEngineering and Rehabilitation, 2015, 12, 114.	2.4	6
207	The neural correlates of motor intentional disorders in patients with subcortical vascular cognitive impairment. Journal of Neurology, 2016, 263, 89-99.	1.8	6
208	Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24â€week prospective randomized openâ€label study (the Korean EXelon Patch and combination with mEmantine Comparative Trial study)*. Geriatrics and Gerontology International, 2017, 17, 494-499.	0.7	6
209	Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer's Disease Using Clinical Research Center for Dementia of South Korea Data. Journal of		

#	Article	IF	Citations
217	Increased Uptake of AV-1451 in a Subacute Infarction Lesion. Yonsei Medical Journal, 2018, 59, 563.	0.9	5
218	Development of wirelessly-powered, extracranial brain activator (ECBA) in a large animal model for the future non-invasive human neuromodulation. Scientific Reports, 2019, 9, 10906.	1.6	5
219	Differences in neuroimaging features of early- versus late-onset nonfluent/agrammatic primary progressive aphasia. Neurobiology of Aging, 2020, 86, 92-101.	1.5	5
220	Identifying a subtype of Alzheimer's disease characterised by predominant right focal cortical atrophy. Scientific Reports, 2020, 10, 7256.	1.6	5
221	Exposure of Mesenchymal Stem Cells to an Alzheimer's Disease Environment Enhances Therapeutic Effects. Stem Cells International, 2021, 2021, 1-14.	1.2	5
222	Subcortical Hypointensity in Partial Status Epilepticus Associated with Nonketotic Hyperglycemia., 2003, 13, 259-263.		5
223	$<$ sup $>$ 18 $<$ /sup $>$ F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in \hat{I}^2 -Amyloid-Negative Amnestic Mild Cognitive Impairment. Yonsei Medical Journal, 2022, 63, 259.	0.9	5
224	Intracerebroventricular Administration of Human Umbilical Cord Blood—Derived Mesenchymal Stem Cells Induces Transient Inflammation in a Transgenic Mouse Model and Patients with Alzheimer's Disease. Biomedicines, 2022, 10, 563.	1.4	5
225	The Brain Donation Program in South Korea. Yonsei Medical Journal, 2018, 59, 1197.	0.9	4
226	Pathologically Confirmed Cerebral Amyloid Angiopathy with No Radiological Sign in a Patient with Early Onset Alzheimer's Disease. Yonsei Medical Journal, 2018, 59, 801.	0.9	4
227	Multimodal imaging analyses in patients with genetic and sporadic forms of small vessel disease. Scientific Reports, 2019, 9, 787.	1.6	4
228	Association between APOE $\hat{l}\mu 2$ and $A\hat{l}^2$ burden in patients with Alzheimer- and vascular-type cognitive impairment. Neurology, 2020, 95, e2354-e2365.	1.5	4
229	Cognitive trajectories of patients with focal ß-amyloid deposition. Alzheimer's Research and Therapy, 2021, 13, 48.	3.0	4
230	Effect of education on functional network edge efficiency in Alzheimer's disease. Scientific Reports, 2021, 11, 17255.	1.6	4
231	A Comparison Study of Cilostazol and Aspirin on Changes in Volume of Cerebral Small Vessel Disease White Matter Changes: Protocol of a Multicenter, Randomized Controlled Trial. Dementia and Neurocognitive Disorders, 2019, 18, 138.	0.4	4
232	Agreement between functional connectivity and cortical thickness-driven correlation maps of the medial frontal cortex. PLoS ONE, 2017, 12, e0171803.	1.1	4
233	Subcortical Ischemic Change as a Predictor of Driving Cessation in the Elderly. Psychiatry Investigation, 2018, 15, 1162-1167.	0.7	4
234	P4-349: A MULTICENTER, RANDOMIZED TRIAL TO ASSESS EFFICACY OF HOME-BASED AND GROUP COGNITIVE INTERVENTION PROGRAMS FOR AMNESTIC MILD COGNITIVE IMPAIRMENT. , 2014, 10, P916-P916.		3

#	Article	IF	Citations
235	A framework to analyze cerebral mean diffusivity using surface guided diffusion mapping in diffusion tensor imaging. Frontiers in Neuroscience, 2015, 9, 236.	1.4	3
236	Extrapyramidal Signs and Cognitive Subdomains in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2016, 24, 566-574.	0.6	3
237	Effect of Illiteracy on Cognition and Cerebral Morphology in Later Life. Dementia and Neurocognitive Disorders, 2015, 14, 149.	0.4	3
238	Amyloid Positive Hydrocephalus: A Hydrocephalic Variant of Alzheimer's Disease?. Journal of Alzheimer's Disease, 2022, 85, 1467-1479.	1.2	3
239	Ethnic differences in the frequency of \hat{l}^2 -amyloid deposition in cognitively normal individuals. Neurobiology of Aging, 2022, 114, 27-37.	1.5	3
240	[¹⁸ F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET		

#	Article	IF	CITATIONS
253	[P4–212]: HEADâ€TOâ€HEAD COMPARISON OF [¹⁸ F] AVâ€1451 AND [¹⁸ F] THK53 IMAGING IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1347.	51 FOR TA 0.4	U 1
254	[P3â€"338]: IN VIVO TAU PET IMAGING IN EARLYâ€ONSET ALZHEIMER's DISEASE AND LATEâ€ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P1083.	.''S _{0.4}	1
255	Intraspinal Cavity Injection of Human Mesenchymal Stem Cells and Tracking their Migration into the Rat Brain. Journal of Visualized Experiments, 2021, , .	0.2	1
256	Quantitative Assessment Method of Force Tracking Capabilities for Detection of Motor Intentional Disorders. Applied Sciences (Switzerland), 2021, 11, 3244.	1.3	1
257	Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 321-330.	3.3	1
258	A Case of Early-Onset Alzheimer's Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P). Journal of Alzheimer's Disease, 2021, 83, 1025-1031.	1.2	1
259	Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2021, 84, 633-645.	1.2	1
260	Developing a Dementia Platform Databank Using Multiple Existing Cohorts. Yonsei Medical Journal, 2021, 62, 1062.	0.9	1
261	Extrapyramidal Signs and Risk of Progression from Mild Cognitive Impairment to Dementia: A Clinical Research Center for Dementia of South Korea Study. Psychiatry Investigation, 2017, 14, 754.	0.7	1
262	Ethnic differences in the frequency of $\hat{l}^2 \hat{a} \in \mathbf{a}$ myloid deposition in cognitively normal individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	1
263	P1-244: EFFECT OF ILLITERACY ON COGNITION AND CEREBRAL MORPHOLOGY IN LATER LIFE. , 2014, 10, P395-P395.		O
264	P3-231: ASSOCIATION OF BODY FAT PERCENTAGE AND WAIST-HIP RATIO WITH BRAIN CORTICAL THICKNESS IN 1,777 COGNITIVELY NORMAL SUBJECTS. , 2014, 10, P715-P716.		0
265	P4-145: BRAINSTEM MICROBLEEDS AFFECT MOTOR DEFICITS IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT., 2014, 10, P842-P842.		O
266	P2-200: MICROSTRUCTURAL CHANGES OF WHITE MATTER IN PURE ALZHEIMER'S DISEASE AND PURE SUBCORTICAL VASCULAR DISEASE., 2014, 10, P545-P545.		O
267	P3-105: CORRELATION OF NOVEL PROTEOMIC ANALYTES WITH ALZHEIMER'S DISEASE BIOMARKERS IN CEREBROSPINAL FLUID FROM MILD SPORADIC ALZHEIMER'S DISEASE DEMENTIA PATIENTS. , 2014, 10, P666-P667.		O
268	P2-208: INCIDENT CEREBRAL MICROBLEEDS IN SUBJECTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: LONGITUDINAL STUDY. , 2014, 10, P548-P549.		O
269	O5-01-01: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P286-P287.		O
270	P3-358: FREQUENCY AND ETIOLOGIES OF EARLY AND LATE ONSET DEMENTIA IN THREE TERTIARY REFERRAL CENTERS IN KOREA. , 2014, 10, P762-P762.		0

#	Article	IF	CITATIONS
271	IC-P-186: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P103-P104.		0
272	P2-187: PATTERNS OF HIPPOCAMPAL SHAPE CHANGES IN PATIENTS WITH FRONTOTEMPORAL DEMENTIA. , 2014, 10, P539-P539.		0
273	P4-067: Tract-specific correlates of cerebrovascular disease and neuropsychological deficits in svci. , 2015, 11, P794-P795.		O
274	P1-188: Synergic effects of amyloid and cerebrovascular disease on cerebral microbleeds: A three-year longitudinal study., 2015, 11, P420-P420.		0
275	P2-140: Neural network of gait disturbances in patients with subcortical vascular cognitive impairment., 2015, 11, P539-P539.		0
276	P2-147: The effect of education on cognition and cortical thickness in pure vascular mild cognitive impairment and dementia of the subcortical type. , 2015, 11, P542-P542.		0
277	P2-142: Pathogenesis of gray and white matter changes in cognitively impaired patients due to Alzheimer's, cerebrovascular disease, and mixed pathologies: Axonal degeneration versus myelin breakdown., 2015, 11, P540-P541.		O
278	P3-100: The distribution and clinical impact of apolipoprotein e4 among patients with subjective memory impairment and early mild cognitive impairment., 2015, 11, P658-P658.		0
279	Analysis on Force Tracking Capabilities of Healthy Adults. Proceedings of the Human Factors and Ergonomics Society, 2015, 59, 726-730.	0.2	0
280	P3-205: Various progression according to anatomic subtypes of Alzheimer's disease., 2015, 11, P711-P711.		0
281	O1-08-01: Distinctive cognitive trajectories related to amyloid and cerebrovascular disease in mild cognitive impairment patients., 2015, 11, P145-P145.		0
282	P4-342: TAU PET Imaging in Semantic Variant Primary Progressive Aphasia Using 18 F-THK5351 PET., 2016, 12, P1166-P1166.		0
283	P1-296: Synergistic Effects of Amyloid and Vascular Changes on The Lobar Microbleeds: A Three-Year Longitudinal Study in Patients With Subcortical Vascular Mild Cognitive Impairment. , 2016, 12, P534-P534.		O
284	P1â€307: Association Enlarged Perivascular Space With Small Vessel Disease and Amyloid Deposition in Cerebral Amyloid Angiopathy Patients. Alzheimer's and Dementia, 2016, 12, P540.	0.4	0
285	P1-409: Detrimental Effects of Coronary Artery Calcification Scores on Cortical Thickness Associated with Patterns of The Default Mode Network in Cognitively Normal Individuals., 2016, 12, P590-P591.		0
286	P2â€239: Effects of Apolipoprotein E Genotype on Progression of Amyloid and Smallâ€Vessel Disease in Subcortical Mild Cognitive Impairment Patients: A Threeâ€Year Longitudinal Study. Alzheimer's and Dementia, 2016, 12, P715.	0.4	0
287	P4â€132: A 3â€Year Analysis of the Progression of Amnestic Mild Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P1064.	0.4	O
288	P4â€183: Regional Amyloid Burden and Lacunar Infarct in Pure Subcortical Vascular Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P1090.	0.4	0

#	Article	IF	CITATIONS
289	P4-208: Longitudinal Cortical Thinning and Cognitive Decline in Patients With Early-Versus Late-Stage Subcortical Vascular Mild Cognitive Impairment., 2016, 12, P1104-P1104.		O
290	ICâ€Pâ€200: [¹⁸ F] T807 PET Imaging in Subcortical Vascular Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P144.	0.4	0
291	P4-219: The Diffuse, Not Focal, Frontal Atrophy Subtype Shows Worse Prognosis in Frontotemporal Dementia., 2016, 12, P1111-P1112.		O
292	IC-P-202: TAU Distribution in Probable CAA. , 2016, 12, P145-P145.		0
293	P4-341: Neurofibrillary Tangle Formation and Synaptic Loss: Which Comes First?., 2016, 12, P1165-P1166.		O
294	[P4–180]: INTERACTIVE INFLUENCE OF DEPRESSION AND APOE 4 ALLELE ON THE DEFAULT MODE NETWOR IN SUBJECTIVE COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1332.	[≀] K.4	0
295	[P1–224]: ¹⁸ Fâ€AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.4	O
296	[P2–406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING ¹⁸ Fâ€THK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.4	0
297	[P2â€"407]: PREVALENCE OF AMYLOIDâ€PET POSITIVITY ACCORDING TO AGE AND <i>APOE </i> PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P787.	0.4	O
298	[P2â€"424]: PROTECTIVE EFFECTS OF EDUCATION ON THKâ€5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT W SUSPECTED NONâ€ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	'ITH 0.4	0
299	[P3–194]: DIAGONAL EARLOBE CREASE, CEREBRAL SMALL VESSEL DISEASE, AND BETAâ€AMYLOIDOSIS IN COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P1009.	0.4	o
300	[P3–258]: TRAJECTORIES OF COGNITIVE DECLINE IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1042.	0.4	0
301	[P3–295]: RELATIONSHIP BETWEEN SLEEP QUALITY AND COGNITION IN PATIENTS WITH SUBJECTIVE MEMORY IMPAIRMENT AND AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1056.	0.4	O
302	[P3–337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.4	0
303	[P3–413]: CLINICAL EFFECT OF SMALLâ€VESSEL DISEASE AND WHITE MATTER NETWORK ON DEPRESSION IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1124.	0.4	O
304	[P4–169]: COGNITIVE TRAJECTORIES IN PATIENTS WITH NONâ€AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2017, 13, P1326.	0.4	0
305	[ICâ€01–03]: RELATIONSHIP AMONG TAU, AMYLOID BURDEN AND BRAIN ATROPHY IN EARLYâ€ONSET ALZHEIN DISEASE AND LATEâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P2.	MER'S 0.4	О
306	[P1â€"358]: CORRELATION BETWEEN AMYLOID IMAGING AND CLINICAL DEMENTIA RATING IN AMNESTIC MILD COGNITIVE IMPAIRMENT AND VERY MILD ALZHEIMER's DISEASE DEMENTIA. Alzheimer's and Dementia, 2017, 13, P395.	0.4	0

#	Article	IF	CITATIONS
307	[P1–365]: PREDOMINANT SUBCORTICAL ¹⁸ Fâ€AVâ€1451 BINDING IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P399.	0.4	О
308	[P1–423]: THE DEVELOPMENT OF AN ALZHEIMER's DISEASE RISK SCORE BASED ON THE CORTICAL THICKNESS ANALYSES. Alzheimer's and Dementia, 2017, 13, P440.	0.4	0
309	[P1–428]: NONâ€ALCOHOLIC FATTY LIVER DISEASE AND CEREBRAL SMALLâ€VESSEL DISEASE IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P443.	0.4	О
310	[P1–454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€5351 UPTAKES IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.4	0
311	[P2â€"267]: IN VIVO TAU DEPOSITION REFLECTS NEUROPSYCHIATRIC SYMPTOMS IN COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P716.	0.4	O
312	[P2â€"318]: RISK SCORE FOR THE PREDICTION OF DEMENTIA RISK IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL, MULTIâ€CENTER CLINICâ€BASED STUDY. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
313	[O4–O4–O3]: SYNERGISTIC EFFECT OF TAU, AMYLOID, AND VASCULAR BURDEN ON COGNITIVE DECLINE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2017, 13, P1235.	0.4	О
314	Node Identification Using Inter-Regional Correlation Analysis for Mapping Detailed Connections in Resting State Networks. Frontiers in Neuroscience, 2017, 11, 238.	1.4	0
315	P1â€382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.4	О
316	P2â€469: THE BRAIN DONATION PROGRAM IN SOUTH KOREA. Alzheimer's and Dementia, 2018, 14, P902.	0.4	0
317	P1â€386: AMYLOID AND CEREBROVASCULAR BURDEN INFLUENCES ON LONGITUDINAL BRAIN FUNCTIONAL CONNECTIVITY CHANGES IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P448.	0.4	O
318	P4â€096: REPLICATING VISUAL ASSESSMENTS OF ¹⁸ Fâ€FLORBETABEN PET USING MACHINE LEARNITECHNIQUE. Alzheimer's and Dementia, 2018, 14, P1473.	ING 0.4	0
319	O1â€14â€01: PULMONARY FUNCTION AND CEREBRAL SMALL VESSEL DISEASE AND CORTICAL THINNING IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P256.	0.4	O
320	P2â€319: DISEASE COURSE MODELING OF ALZHEIMER'S DISEASE DEPENDING ON AMYLOID DEPOSITION: AN ACCELERATED LONGITUDINAL DESIGN. Alzheimer's and Dementia, 2018, 14, P804.	0.4	0
321	ICâ€Pâ€121: EFFECTS OF CARDIOMETABOLIC RISK FACTORS ON BRAIN AGING IN THE ELDERLY. Alzheimer's and Dementia, 2018, 14, P102.	0.4	О
322	P1â€407: ALZHEIMER'S DISEASE WITH RIGHT FOCAL CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P459.	0.4	0
323	ICâ€Pâ€078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. Alzheimer's and Dementia, 2018, 14, P69.	0.4	О
324	O3â€10â€01: DIFFERENT EFFECTS OF APOE ε4 ALLELE ON THE RELATIONSHIP BETWEEN TAU AND βâ€AMYLOID EARLYâ€ONSET AND LATEâ€ONSET ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P1039.	IN 0.4	0

#	Article	IF	CITATIONS
325	ICâ€Pâ€014: REPLICATING VISUAL ASSESSMENTS OF ¹⁸ Fâ€FLORBETABEN PET USING MACHINE LEATECHNIQUE. Alzheimer's and Dementia, 2018, 14, P22.	RNING 0.4	0
326	ICâ€Pâ€079: MACHINE LEARNING–BASED CLASSIFICATION OF ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA CLINICAL SYNDROMES. Alzheimer's and Dementia, 2018, 14, P69.	0.4	0
327	ICâ€P‶42: SURFACEâ€BASED MULTIMODAL CLUSTER ANALYSIS REVEALS TOPOGRAPHICAL HETEROGENEITY C ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P118.	0F 0.4	O
328	P3â€393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT Alzheimer's and Dementia, 2018, 14, P1248.	^{Г.} о.4	0
329	O1â€14â€03: NATURAL HISTORY OF SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: AN 8.5â€YEAR LONGITU STUDY. Alzheimer's and Dementia, 2018, 14, P258.	JDINAL 0.4	0
330	P1â€483: COGNITIVE RESERVE AND EFFICIENCY NETWORK: IN NORMAL COGNITION, AMNESTIC MCI AND ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P511.	0.4	0
331	P3â€346: CLINICAL SIGNIFICANCE OF AMYLOID BETA POSITIVITY IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY MARKERS. Alzheimer's and Dementia, 2018, 14, P1216.	0.4	0
332	ICâ€Pâ€050: AMYLOID DEPOSITION IN THE SUBCORTICAL REGION PREDICTS COGNITIVE DECLINE. Alzheimer's ar Dementia, 2018, 14, P49.	nd 0.4	0
333	P4â€104: CLINICAL SIGNIFICANCE OF FOCAL ¹⁸ Fâ€FLUTEMETAMOL UPTAKE. Alzheimer's and Dementia, 2018, 14, P1478.	0.4	0
334	P3â€425: ALZHEIMER'S DEMENTIA CONVERSION IN AMNESTIC MCI ACCORDING TO NEUROPSYCHOLOGICAL PROFILE. Alzheimer's and Dementia, 2018, 14, P1272.	0.4	0
335	P1â€383: ¹⁸ Fâ€FLORTAUCIPIR BINDING PATTERNS IN CLINICAL SUBTYPES OF PRIMARY PROGRESSI' APHASIA. Alzheimer's and Dementia, 2018, 14, P446.	VE 6.4	O
336	ICâ€Pâ€211: IDENTIFICATION OF HETEROGENEOUS GROUPS OF MILD COGNITIVE IMPAIRMENT BASED ON [¹⁸ F]THK5351 RETENTION PATTERNS. Alzheimer's and Dementia, 2018, 14, P173.	0.4	0
337	P1â€505: THE CLINICAL USEFULNESS AND VALIDITY OF THE NOVEL TABLETâ€BASED COGNITIVE SCREENING TES PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P523.	0.4	0
338	P3â€339: MACHINE LEARNING–BASED CLASSIFICATION OF ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA CLINICAL SYNDROMES. Alzheimer's and Dementia, 2018, 14, P1212.	0.4	0
339	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 69, 213-225.	1.2	O
340	The effect of smartphone appâ€based cognitive training on cognition in communityâ€dwelling elderly: A randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e039268.	0.4	0
341	Optical coherence tomography angiography in cognitively impaired patients: Vascular and neurodegenerative perspectives. Alzheimer's and Dementia, 2020, 16, e041738.	0.4	O
342	Impact of APOE e4 on cognitive trajectory in earlyâ€onset vs lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042218.	0.4	0

#	Article	IF	Citations
343	H. pylori infection is associated with cortical thinning in cognitively normal individuals. Alzheimer's and Dementia, 2020, 16, e044295.	0.4	O
344	Two cases of non-fluent variant primary progressive aphasia with different pathological diagnoses. Precision and Future Medicine, 2021, 5, 142-148.	0.5	0
345	Cognitive Intervention in a Patient with Carbon Monoxide Intoxication. Dementia and Neurocognitive Disorders, 2014, 13, 139.	0.4	0
346	Honorific Speech Impairment: A Characteristic Sign of Frontotemporal Dementia. Cognitive and Behavioral Neurology, 2021, 34, 275-287.	0.5	0
347	Machine learning for the prediction of amyloid positivity in amnestic mild cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0
348	Hidden objective test. Alzheimer's and Dementia, 2021, 17, .	0.4	0
349	Clinical outcomes of increased regional amyloid uptake in patients with subthreshold global amyloid levels. Alzheimer's and Dementia, 2021, 17, .	0.4	0
350	Distinctive Mediating Effects of Subcortical Structure Changes on the Relationships Between Amyloid or Vascular Changes and Cognitive Decline. Frontiers in Neurology, 2021, 12, 762251.	1.1	0
351	Survival in Korean Patients with Frontotemporal Dementia Syndrome: Association with Behavioral Features and Parkinsonism. Journal of Clinical Medicine, 2022, 11, 2260.	1.0	О